Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05949294 |
Recruitment Status :
Withdrawn
(Company business decision)
First Posted : July 18, 2023
Last Update Posted : April 17, 2024
|
Sponsor:
Arrowhead Pharmaceuticals
Information provided by (Responsible Party):
Arrowhead Pharmaceuticals
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
In this Phase 1 adult symptomatic patients with amyotrophic lateral sclerosis (ALS) carrying a superoxide dismutase 1 (SOD1) gene mutation thought to be causative of ALS, will receive single ascending doses of ARO-SOD1 administered by intrathecal (IT) infusion. The study is primarily intended to evaluate safety, but will also evaluate the effect of ARO-SOD1 on SOD1 cerebrospinal fluid (CSF) levels as a biomarker of pharmacodynamic (PD) effect, therefore lumbar punctures will be required at timepoints throughout the study. After each participant has completed their individual final visit, participants whose SOD1 CSF levels have recovered to a satisfactory level may rescreen and enroll into higher dose cohorts; or if unable or unwilling to rescreen may enroll into an open-label study to be added by amendment when supported by nonclinical data for multidose administration.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Amyotrophic Lateral Sclerosis | Drug: ARO-SOD1 Injection | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | N/A |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ARO-SOD1 in Adult Patients With Amyotrophic Lateral Sclerosis Harboring a Superoxide Dismutase-1 Mutation Considered to be Causative of Amyotrophic Lateral Sclerosis |
Estimated Study Start Date : | January 2024 |
Estimated Primary Completion Date : | March 2025 |
Estimated Study Completion Date : | March 2025 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Amyotrophic lateral sclerosis
MedlinePlus related topics:
Amyotrophic Lateral Sclerosis
Arm | Intervention/treatment |
---|---|
Experimental: ARO-SOD1
ARO-SOD1 Injection
|
Drug: ARO-SOD1 Injection
single doses of ARO-SOD1 Injection by IT infusion |
Primary Outcome Measures :
- Number of Participants with Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: From first dose of study drug through the end of study (EOS; up to 168 days) ]
Secondary Outcome Measures :
- Change Over Time from Baseline in CSF SOD1 Protein Levels [ Time Frame: Pre-dose on Day 1 (Baseline) through EOS (up to 168 days) ]
- Change Over Time from Baseline in Plasma Levels of Neurofilament Light Chain (NfL) [ Time Frame: Pre-dose on Day 1 (Baseline) through EOS (up to 168 days) ]
- Pharmacokinetics (PK) of ARO-SOD1: Maximum Observed Plasma Concentration (Cmax) [ Time Frame: Days 1, 2, 15, 29, 57, 85 and EOS (Day 168): Pre-dose, post-dose at 1, 3, 5, 7, 12 and 24 hours ]
- PK of ARO-SOD1: Time to Reach Maximum Observed Plasma Concentration (Tmax) [ Time Frame: Days 1, 2, 15, 29, 57, 85 and EOS (Day 168): Pre-dose, post-dose at 1, 3, 5, 7, 12 and 24 hours ]
- PK of ARO-SOD1: Area Under the Plasma Concentration Versus Time Curve from Zero to 24 Hours (AUC0-24) [ Time Frame: Days 1, 2, 15, 29, 57, 85 and EOS (Day 168): Pre-dose, post-dose at 1, 3, 5, 7, 12 and 24 hours ]
- PK of ARO-SOD1: Area Under the Plasma Concentration Versus Time Curve from Zero to the Last Quantifiable Plasma Concentration (AUClast) [ Time Frame: Days 1, 2, 15, 29, 57, 85 and EOS (Day 168): Pre-dose, post-dose at 1, 3, 5, 7, 12 and 24 hours ]
- PK of ARO-SOD1: Area Under the Plasma Concentration Versus Time Curve from Zero to Infinity (AUCinf) [ Time Frame: Days 1, 2, 15, 29, 57, 85 and EOS (Day 168): Pre-dose, post-dose at 1, 3, 5, 7, 12 and 24 hours ]
- PK of ARO-SOD1: Terminal Elimination Half-Life (t1/2) [ Time Frame: Days 1, 2, 15, 29, 57, 85 and EOS (Day 168): Pre-dose, post-dose at 1, 3, 5, 7, 12 and 24 hours ]
- PK of ARO-SOD1: Apparent Systemic Clearance (CL/F) [ Time Frame: Days 1, 2, 15, 29, 57, 85 and EOS (Day 168): Pre-dose, post-dose at 1, 3, 5, 7, 12 and 24 hours ]
- PK of ARO-SOD1: Recovery of Unchanged Drug in Urine Over 0-24 Hours (Amount Excreted: Ae) [ Time Frame: Pre-dose through 24 hours post-dose ]
- PK of ARO-SOD1: Percentage of Administered Drug Recovered in Urine Over 0-24 Hours [ Time Frame: Pre-dose through 24 hours post-dose ]
- PK of ARO-SOD1: Renal Clearance (CLr) [ Time Frame: Pre-dose through 24 hours post-dose ]
- Change From Baseline in Total Protein in CSF [ Time Frame: Pre-dose on Day 1 (Baseline) through EOS (up to 168 days) ]
- Change From Baseline in Glucose in CSF [ Time Frame: Pre-dose on Day 1 (Baseline) through EOS (up to 168 days) ]
- Change From Baseline in Cell Count in CSF [ Time Frame: Pre-dose on Day 1 (Baseline) through EOS (up to 168 days) ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Diagnosis of ALS based on source-verifiable medical record and meets the Gold Coast Criteria
- Pathogenic or likely pathogenic SOD1 mutation based on source-verifiable medical records or genetic testing during Screening
- Slow Vital Capacity (SVC) ≥ 50% of predicted value adjusted for sex, age, and height (from a sitting position) at Screening
- Body Mass Index (BMI) ≥ 18.0 kg/m2 at Screening
- Able to complete at least 6 months of follow-up
- If taking any medication or supplement to treat ALS or ALS symptoms, must be on stable dose for ≥ 4 weeks prior to Day 1 and expected to remain at that dose until final study visit and not expected to start these medications after the first dose of ARO-SOD1
- Able and willing to provide written informed consent and to comply with all study assessments
- Participants of childbearing potential must agree to use highly effective contraception in addition to a condom during the study and for at least 90 days following the end of study or last dose of study drug, whichever is later. Males must not donate sperm and females must not donate eggs during the study and for at least 90 days following the end of the study or last dose of study drug, whichever is later.
Exclusion Criteria:
- Current or anticipated need of a diaphragm pacing system (DPS) during the study
- Participants using tofersen can be enrolled only after a washout period of approximately 20 weeks from the last tofersen dose to the first planned dose of ARO-SOD1
- History of having received stem cell therapy for ALS treatment
- Any current or anticipated contraindications to lumbar puncture (LP)
- The presence of an implanted shunt for drainage of CSF or an implanted central nervous system (CNS) catheter
- Human immunodeficiency virus (HIV), seropositive for hepatitis B virus (HBV), seropositive for hepatitis C virus (HCV)
- Uncontrolled hypertension
- Severe cardiovascular disease
- History of drug abuse or alcoholism within 6 months of study enrollment
- Inability to comply with study requirements
Note: additional inclusion/exclusion criteria may apply per protocol
No Contacts or Locations Provided
Responsible Party: | Arrowhead Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT05949294 |
Other Study ID Numbers: |
AROSOD1-1001 2023-509032-26 ( EudraCT Number ) |
First Posted: | July 18, 2023 Key Record Dates |
Last Update Posted: | April 17, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
Additional relevant MeSH terms:
Motor Neuron Disease Amyotrophic Lateral Sclerosis Sclerosis Pathologic Processes Neurodegenerative Diseases Nervous System Diseases |
Neuromuscular Diseases Spinal Cord Diseases Central Nervous System Diseases TDP-43 Proteinopathies Proteostasis Deficiencies Metabolic Diseases |